Skip to main content

Table 1 Subject Characteristics

From: Integrated robotics platform with haptic control differentiates subjects with Parkinson’s disease from controls and quantifies the motor effects of levodopa

Subject

Age (yrs)

Sex

Disease duration (yrs)

Levodopa dose (mg)

Other parkinsonian medications

Other drug dosages (mg)

UPDRS motor OFF

UPDRS motor ON

MoCA

PD01

48

M

0.5

600

None

0

21

12

26

PD02

55

M

6

600

None

0

26

12

25

PD03a

71

M

5

800

Entacapone

400

54

26

21

PD04

67

M

5

700

Rasagiline, Pramipexole

1, 0.25

22

11

27

PD05 a

70

M

15

700

Entacapone

400

34

38

24

PD06a

67

M

11

400

Amantadine

200

46

13

22

PD07

55

M

3

550

None

0

30

24

30

PD08

72

M

13

350

None

0

33

22

27

PD09

57

M

4

600

None

0

12

7

27

PD10a

69

M

6

875

None

0

29

16

26

PD11

72

M

8

450

Pramipexole

1

28

22

26

PD12

70

F

5

650

Entacapone

200

28

10

28

PD13

53

F

2

1100

None

0

48

29

25

PD14

61

F

3

300

None

0

24

15

29

PD15

73

M

3

600

Pramipexole

3

18

7

25

PD16 a

75

M

8

500

Pramipexole

4.5

23

21

26

PD17

69

F

5

600

Pramipexole

1

38

27

25

PD18

72

M

5

1000

Pramipexole

3

33

17

20

PD19a

68

M

5

1050

Pramipexole

0.75

42

16

25

PD20

75

M

3

950

None

0

8

5

27

PD21a

58

M

5

600

Trihexyphenidyl

3

20

5

24

PD22a

54

F

4

450

Propranolol

60

27

16

26

PD23a

75

F

8

600

None

0

37

22

25

PD24

47

M

3

450

None

0

27

11

26

PD25a

64

M

6

1000

Rotigotine patch

4

35

6

21

PD26

71

F

2

400

None

0

29

18

25

  1. aSignifies a change in symmetry between OFF and ON; bolding of subject number represents a failure to achieve a minimal clinical difference 1 hour after DRT administration